Josh Bilenker
CEO Loxo Oncology at Lilly in Stamford, CT, US
Joshua H. Bilenker, MD, holds CEO responsibilities with Loxo Oncology at Lilly and oversees oncology research and development efforts. Based in Stamford, Connecticut, he oversees activities ranging from target selection through first US approval. Dr. Bilenker helped reorient Loxo’s translational and biology research efforts towards a smaller number of high conviction programs.
Dr. Bilenker areas of content focus have included healthcare finance, rational drug design, oncology precision medicine clinical-regulatory development. He is a frequent invited speaker at academic medical meetings and patient advocacy events.
Dr. Bilenker’s work experience includes a position with the U.S. Food and Drug Administration as a medical officer. In this role, he was tasked with making regulatory judgments when it came to biologic licensing and investigational new drug applications. Launching Loxo Oncology in 2013, Dr. Josh Bilenker oversaw the successful development of drugs such as Retevmo and Vitrakvi. Loxo Oncology also acquired LOXO-305 from Redx Pharma, which is in Phase 2 clinical development at Loxo at Lilly.